62
Vaxcyte prices $575M convertible notes due 2032 at 1.50% interest
Why it matters
Vaxcyte completed a $575 million convertible debt offering at 1.50% with a 2032 maturity and $89.60 conversion price, representing a material capital raise. The conversion terms and redemption provisions are typical for convertible instruments, and near-term dilution depends on stock performance relative to the conversion price; the neutral direction reflects offsetting effects of capital access and future dilution.
In plain language
Vaxcyte raised $575 million by selling bonds that can be converted into stock later. If the stock price rises enough, bondholders may convert to shares, which could dilute existing shareholders.
Exposure
Price check
not measured: no fresh price at the time of scoringHow this is measured
Information only. AURA does not give buy or sell recommendations.